查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1830993

經由黏膜給藥系統市場

Transmucosal Drug Delivery Systems Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

經黏膜給藥系統市場規模預計將從2024年的820.2億美元成長到2031年的1,294.6億美元，2025年至2031年期間的複合年成長率為6.2%。分析師觀點：經黏膜給藥利用黏膜（包括口腔、鼻腔、直腸、陰道、眼部及肺部黏膜）進行給藥。與傳統給藥途徑相比，此方法具有顯著優勢，例如生物利用度更高、起效更快、避免首過代謝以及給藥便捷。本報告根據經黏膜給藥系統市場的當前趨勢及其在預測期內的預期影響，重點介紹了成長機會。

推動經黏膜給藥系統成長的因素

經黏膜給藥因其持續的療效而備受青睞。鼻腔內、頰部、舌下和直腸給藥等非侵入性給藥方式無需專業人員即可進行全身給藥，這對護理人員和患者尤其有益。此外，這些方法迅速且首過代謝降低，使其成為安寧療護和臨終關懷的理想選擇，能夠快速緩解症狀。因此，經粘膜給藥系統擴大用於治療心血管疾病、糖尿病和慢性呼吸系統疾病等慢性疾病。 PubMed Central 於 2020 年 1 月發表的一項研究，評估了二氫麥角胺 (DHE) 在健康受試者中的安全性和藥物動力學，研究內容包括經鼻 DHE 粉劑 (STS101)、經鼻 DHE 噴霧劑 (Migranal) 和肌肉注射 (IM) DHE。研究結果表明，STS101 是一種方便用戶使用的非注射偏頭痛急性治療方法，具有良好的耐受性，有望提供快速、持續的疼痛緩解，同時抑制偏頭痛症狀且不復發。

許多藥物都有口腔黏膜劑型，包括心血管藥物、鎮靜劑和止痛劑。可生物分解的口腔膜有助於藥物傳遞到體循環，這對吞嚥困難、頻繁嘔吐、高血壓、心臟病發作、氣喘、噁心、癱瘓和精神健康障礙患者尤其有利。這些速溶口腔膜是貼在舌頭或其他口腔黏膜組織上的薄黏性條帶。

因此，易於管理、生物利用度高、全身藥物可用性和快速作用的優勢正在推動經黏膜給藥系統市場的成長。

戰略洞察

報告細分和範圍

《2031年全球經黏膜給藥系統市場分析》是一項針對製藥業的綜合性研究，重點在於分析全球市場趨勢。該報告旨在提供市場概覽，並根據系統、最終用戶和地理進行詳細細分。報告包含主要市場參與者的關鍵統計數據，並重點介紹了市場中的重要趨勢和機會。全球經黏膜給藥系統市場報告涵蓋北美（美國、加拿大和墨西哥）、歐洲（德國、法國、義大利、英國、西班牙和歐洲其他地區）、亞太地區（中國、日本、印度、澳洲、韓國和亞太其他地區）、中東和非洲（南非、沙烏地阿拉伯、阿拉伯聯合大公國和中東和非洲其他地區）以及南美洲和中美洲（巴西、阿根廷和南美洲和中美洲其他地區）。

以系統為基礎的洞察市場分為鼻肺給藥系統、頰黏膜及舌下給藥系統、陰道給藥系統及其他系統。 2023年，鼻肺給藥系統佔據了經黏膜給藥系統市場的最大佔有率，預計在2023年至2031年期間將呈現最高的複合年成長率。

基於最終用戶的洞察市場根據最終用戶分為醫療機構、家庭護理機構和其他類型。醫療機構在2023年佔據了最大的市場佔有率，這要歸功於醫院擁有一流的設施和經驗豐富的醫療專業人員。此外，預計家庭護理機構在2023年至2031年期間的複合年成長率最高。

區域分析：從地理上看，市場細分為北美、亞太、歐洲、中東和非洲以及南美和中美。 2023年，北美佔據了經黏膜給藥系統市場的最大佔有率，其中美國佔據主導地位。這種主導地位的形成源於糖尿病、氣喘和心血管疾病等慢性疾病的發病率不斷上升，以及主要產業參與者推出的產品數量不斷增加。

經黏膜給藥系統市場報告範圍：產業發展與未來機會：經黏膜給藥系統市場的預測可以幫助利害關係人規劃其成長策略。根據公司新聞稿，全球市場領導企業的幾項策略發展概述如下：

2024年2月，Aquestive Therapeutics, Inc. 在華盛頓特區舉行的美國過敏、氣喘和免疫學會 (AAAAI) 2024 年年會上展示了一張海報，展示了兩項已完成的舌下 Anaphylm（腎上腺素）膜臨床研究的陽性藥物動力學 (PK) 和藥效學 (PD)資料。 2022年8月，iX Biopharma Ltd 啟動了 IXB-322，這是一項擴展其產品線的新計劃，專注於開發用於治療失智症和其他疾病中的躁動的舌下右美托咪啶薄片。此項努力是 iX Biopharma 利用其專有的 WaferiX 藥物傳輸平台技術重新利用現有核准藥物的策略的一部分。 2021 年 5 月，日本 Zeria 集團旗下的 Tillotts Pharma AG 推出了 AsacolTM 1g（美沙拉嗪），為其胃腸病學產品組合增添了一種新藥，這是一種用於治療成人輕度至中度潰瘍性直腸炎症狀的高強度栓劑。此次發布旨在為胃腸道疾病患者提供創新療法，提供一種每日只需服用一次的便捷治療選擇。 2021年4月，梯瓦製藥工業有限公司的美國分公司梯瓦製藥美國公司宣佈在美國推出Casana 1（美沙拉嗪）栓劑的學名藥，用於治療活動性潰瘍性直腸炎（潰瘍性直腸結腸炎）。經黏膜給藥系統市場報告中介紹的主要公司包括梯瓦製藥工業有限公司、信諾集團、BioDelivery Sciences International, Inc、3M、漢高芬蘭公司、葛蘭素史克公司、Aquestive Therapeutics, Inc、Camurus AB、Ximedica和Noven Pharmaceuticals, Inc.。這些領導企業專注於擴大和多樣化其市場佔有率和客戶群，抓住市場商機。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解
  • 市場吸引力分析

第3章：研究方法

第4章：經黏膜給藥系統市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈中的供應商列表

第5章：經黏膜給藥系統市場－關鍵市場動態

  • 關鍵市場促進因素
  • 主要市場限制因素
  • 關鍵市場機會
  • 未來趨勢
  • 促進因素和限制因素的影響分析

第6章：經黏膜給藥系統市場－全球市場分析

  • 經黏膜給藥系統－全球市場概覽
  • 經黏膜給藥系統－全球市場及2031年預測

第7章：經黏膜給藥系統市場-收入分析-按系統，2021-2031

  • 概述
  • 鼻肺
  • 頰部和舌下
  • 陰道
  • 其他

第 8 章：經黏膜給藥系統市場 - 收入分析 - 按最終用戶，2021-2031 年

  • 概述
  • 醫療保健設施
  • 居家照護環境
  • 其他

第9章：經黏膜給藥系統市場－收入分析，2021-2031－地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第10章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 11 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與集中度

第 12 章：經黏膜給藥系統市場 - 關鍵公司簡介

  • Teva Pharmaceutical Industries Ltd
  • Cigna Corporation
  • BioDelivery Sciences International, Inc
  • 3M
  • Henkel Finland Oy
  • GlaxoSmithKline plc
  • Aquestive Therapeutics, Inc
  • Camurus AB
  • Ximedica
  • Noven Pharmaceuticals, Inc

第 13 章：附錄

簡介目錄
Product Code: TIPRE00004209

The transmucosal drug delivery systems market is projected to increase from US$ 82.02 billion in 2024 to US$ 129.46 billion by 2031, with an estimated CAGR of 6.2% during the period from 2025 to 2031.

Analyst Perspective

Transmucosal drug delivery utilizes mucosal membranes, including oral, nasal, rectal, vaginal, ocular, and pulmonary mucosa, for administering drugs. This method offers significant advantages over traditional drug delivery routes, such as enhanced bioavailability, quick onset of action, avoidance of first-pass metabolism, and ease of administration. The report highlights growth opportunities based on current trends in the transmucosal drug delivery systems market and their anticipated effects throughout the forecast period.

Factors Propelling Growth in Transmucosal Drug Delivery Systems

Transmucosal drug delivery is favored for its sustained effectiveness. Noninvasive methods like intranasal, buccal, sublingual, and rectal routes allow for systemic drug delivery without the need for specialized personnel, making them particularly beneficial for caregivers and patients. Additionally, the rapid onset of action and reduced first-pass metabolism make these methods ideal for palliative and end-of-life care, providing quick symptom relief. Consequently, transmucosal delivery systems are increasingly utilized in managing chronic conditions such as cardiovascular diseases, diabetes, and chronic respiratory diseases. A study published by PubMed Central in January 2020 examined the safety and pharmacokinetics of dihydroergotamine (DHE) administered as intranasal DHE powder (STS101), intranasal DHE spray (Migranal), and intramuscular (IM) DHE injection in healthy subjects. The findings indicated that STS101 is a user-friendly, non-injected acute treatment for migraines with a favorable tolerability profile, expected to provide rapid and consistent pain relief while suppressing migraine symptoms without recurrence.

Many pharmacological agents are available in oral transmucosal forms, including cardiovascular drugs, sedatives, and analgesics. Biodegradable oral films facilitate drug delivery into systemic circulation, which is particularly advantageous for patients with dysphagia, frequent vomiting, hypertension, heart attacks, asthma, nausea, paralysis, and mental health disorders. These fast-dissolving oral films are thin adhesive strips placed on the tongue or other oral mucosal tissues.

Thus, the benefits of easy administration, high bioavailability, systemic drug availability, and rapid action are driving the growth of the transmucosal drug delivery systems market.

Strategic Insights

Report Segmentation and Scope

The "Global Transmucosal Drug Delivery Systems Market Analysis to 2031" is a comprehensive study of the pharmaceutical sector, focusing on global market trend analysis. The report aims to provide an overview of the market with detailed segmentation based on systems, end users, and geography. It includes key statistics on leading market players and highlights significant trends and opportunities in the market. The scope of the global transmucosal drug delivery systems market report covers North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Insights Based on Systems

The market is categorized into nasopulmonary, buccal & sublingual, vaginal, and other systems. The nasopulmonary segment accounted for the largest share of the transmucosal drug delivery systems market in 2023 and is expected to exhibit the highest CAGR from 2023 to 2031.

Insights Based on End Users

The market is divided into healthcare facilities, homecare settings, and others based on end users. The healthcare facilities segment held the largest market share in 2023, attributed to the availability of superior facilities and skilled healthcare professionals in hospitals. Furthermore, the homecare settings segment is projected to experience the highest CAGR from 2023 to 2031.

Regional Analysis

Geographically, the market is segmented into North America, Asia Pacific, Europe, the Middle East & Africa, and South & Central America. North America held the largest share of the transmucosal drug delivery systems market in 2023, with the US leading this region. This dominance is due to the rising prevalence of chronic diseases such as diabetes, asthma, and cardiovascular conditions, along with an increasing number of product launches by key industry players.

Scope of the Transmucosal Drug Delivery Systems Market Report

Industry Developments and Future Opportunities:The forecast for the transmucosal drug delivery systems market can assist stakeholders in planning their growth strategies. According to company press releases, several strategic developments by leading players in the global market are outlined below:

In February 2024, Aquestive Therapeutics, Inc. showcased a poster at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2024 annual meeting in Washington, DC, presenting positive pharmacokinetic (PK) and pharmacodynamic (PD) data from two completed clinical studies on sublingual Anaphylm (epinephrine) film.

In August 2022, iX Biopharma Ltd launched IXB-322, a new initiative to expand its pipeline, focusing on developing a sublingual dexmedetomidine wafer for treating agitation in dementia and other conditions. This effort is part of iX Biopharma's strategy to repurpose existing approved drugs using its proprietary WaferiX drug delivery platform technology.

In May 2021, Tillotts Pharma AG, part of the Japanese Zeria Group, introduced a new medication to its gastroenterology portfolio with the launch of AsacolTM 1g (mesalazine), a high-strength suppository for treating mild to moderate ulcerative proctitis symptoms in adults. This launch aims to provide innovative therapies for patients with gastrointestinal diseases, offering a convenient treatment option requiring only a single daily dose.

In April 2021, Teva Pharmaceuticals USA, Inc., a US affiliate of Teva Pharmaceutical Industries Ltd., announced the launch of its generic version of Casana 1 (mesalamine) suppository medicine, indicated for treating active ulcerative proctitis (ulcerative rectal colitis) in the US.

Key companies profiled in the transmucosal drug delivery systems market report include Teva Pharmaceutical Industries Ltd, Cigna Corporation, BioDelivery Sciences International, Inc, 3M, Henkel Finland Oy, GlaxoSmithKline plc, Aquestive Therapeutics, Inc, Camurus AB, Ximedica, and Noven Pharmaceuticals, Inc. These leading players are focused on expanding and diversifying their market presence and clientele, seizing business opportunities in the market.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Transmucosal Drug Delivery Systems Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Transmucosal Drug Delivery Systems Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Transmucosal Drug Delivery Systems Market - Global Market Analysis

  • 6.1 Transmucosal Drug Delivery Systems - Global Market Overview
  • 6.2 Transmucosal Drug Delivery Systems - Global Market and Forecast to 2031

7. Transmucosal Drug Delivery Systems Market - Revenue Analysis (USD Million) - By System, 2021-2031

  • 7.1 Overview
  • 7.2 Nasopulmonary
  • 7.3 Buccal and Sublingual
  • 7.4 Vaginal
  • 7.5 Others

8. Transmucosal Drug Delivery Systems Market - Revenue Analysis (USD Million) - By End User, 2021-2031

  • 8.1 Overview
  • 8.2 Healthcare Facilities
  • 8.3 Homecare settings
  • 8.4 Others

9. Transmucosal Drug Delivery Systems Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Transmucosal Drug Delivery Systems Market Overview
    • 9.1.2 North America Transmucosal Drug Delivery Systems Market Revenue and Forecasts to 2031
    • 9.1.3 North America Transmucosal Drug Delivery Systems Market Revenue and Forecasts and Analysis - By System
    • 9.1.4 North America Transmucosal Drug Delivery Systems Market Revenue and Forecasts and Analysis - By End User
    • 9.1.5 North America Transmucosal Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Countries
      • 9.1.5.1 United States Transmucosal Drug Delivery Systems Market
        • 9.1.5.1.1 United States Transmucosal Drug Delivery Systems Market, by System
        • 9.1.5.1.2 United States Transmucosal Drug Delivery Systems Market, by End User
      • 9.1.5.2 Canada Transmucosal Drug Delivery Systems Market
        • 9.1.5.2.1 Canada Transmucosal Drug Delivery Systems Market, by System
        • 9.1.5.2.2 Canada Transmucosal Drug Delivery Systems Market, by End User
      • 9.1.5.3 Mexico Transmucosal Drug Delivery Systems Market
        • 9.1.5.3.1 Mexico Transmucosal Drug Delivery Systems Market, by System
        • 9.1.5.3.2 Mexico Transmucosal Drug Delivery Systems Market, by End User
  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 France
    • 9.2.3 Italy
    • 9.2.4 Spain
    • 9.2.5 United Kingdom
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 Australia
    • 9.3.2 China
    • 9.3.3 India
    • 9.3.4 Japan
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 Middle East and Africa
    • 9.4.1 South Africa
    • 9.4.2 Saudi Arabia
    • 9.4.3 U.A.E
    • 9.4.4 Rest of Middle East and Africa
  • 9.5 South and Central America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of South and Central America

10. Industry Landscape

  • 10.1 Mergers and Acquisitions
  • 10.2 Agreements, Collaborations, Joint Ventures
  • 10.3 New Product Launches
  • 10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

  • 11.1 Heat Map Analysis by Key Players
  • 11.2 Company Positioning and Concentration

12. Transmucosal Drug Delivery Systems Market - Key Company Profiles

  • 12.1 Teva Pharmaceutical Industries Ltd
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Cigna Corporation
  • 12.3 BioDelivery Sciences International, Inc
  • 12.4 3M
  • 12.5 Henkel Finland Oy
  • 12.6 GlaxoSmithKline plc
  • 12.7 Aquestive Therapeutics, Inc
  • 12.8 Camurus AB
  • 12.9 Ximedica
  • 12.10 Noven Pharmaceuticals, Inc

13. Appendix

  • 13.1 Glossary
  • 13.2 About The Insight Partners
  • 13.3 Market Intelligence Cloud